PRINCETON, N.J.--(BUSINESS WIRE)--PharmaNet Development Group, Inc. (the “Company”) (NASDAQ: PDGI), a leading provider of global drug development services to branded pharmaceutical, biotechnology, generic drug and medical device companies, today reported GAAP net earnings from continuing operations for the fourth quarter ended December 31, 2007, of $3.8 million, or $0.20 per diluted share, compared to GAAP net earnings from continuing operations of $3.5 million, or $0.19 per diluted share, in the fourth quarter 2006.
